[Interferon-beta treatment in patients with childhood-onset and juvenile multiple sclerosis].
Prospectively observed natural history in 10 cases of pediatric multiple sclerosis (MS), with respect to prognosis comparing to that of adult-onset MS (n=100) is presented. Poor-prognosis with severe disability was found in juvenile MS (age at onset 10-16 years old) with high annual rate of relapses in 2 years after the disease onset. The results of the long-term (2.0 to 3.5 years) beta-interferon treatment in patients with juvenile MS and the factors affecting these results are analyzed. Based on these data, together with those of published controlled clinical trials in adult-onset MS, indications for beta-interferon therapy and peculiarities of the treatment are discussed.
Totolian
N A
NA
Skoromets
A A
AA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D001921:Brain / Q000473:pathology; D002648:Child; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy*; D011446:Prospective Studies; D012720:Severity of Illness Index
D000276:Adjuvants, Immunologic; D016899:Interferon-beta